## 2006 SESSION

060499316 **HOUSE BILL NO. 355** 1 2 AMENDMENT IN THE NATURE OF A SUBSTITUTE 3 (Proposed by the House Committee on Health, Welfare and Institutions) 4 (Patrons Prior to Substitute—Delegates Hamilton and Jones, S.C. [HB 290]) 5 6 House Amendments in [] - February 9, 2006 A BILL to amend and reenact §§ 2.2-4006 and 54.1-3307 of the Code of Virginia, relating to specific 7 powers and duties of the Board of Pharmacy. 8 Be it enacted by the General Assembly of Virginia: 9 1. That §§ 2.2-4006 and 54.1-3307 of the Code of Virginia are amended and reenacted as follows: 10 § 2.2-4006. Exemptions from requirements of this article. 11 A. The following agency actions otherwise subject to this chapter and § 2.2-4103 of the Virginia Register Act shall be exempted from the operation of this article: 12 13 1. Agency orders or regulations fixing rates or prices. 14 2. Regulations that establish or prescribe agency organization, internal practice or procedures, 15 including delegations of authority. 3. Regulations that consist only of changes in style or form or corrections of technical errors. Each 16 17 promulgating agency shall review all references to sections of the Code of Virginia within their regulations each time a new supplement or replacement volume to the Code of Virginia is published to 18 19 ensure the accuracy of each section or section subdivision identification listed. 20 4. Regulations that are: 21 a. Necessary to conform to changes in Virginia statutory law or the appropriation act where no 22 agency discretion is involved; 23 b. Required by order of any state or federal court of competent jurisdiction where no agency 24 discretion is involved: or 25 c. Necessary to meet the requirements of federal law or regulations, provided such regulations do not differ materially from those required by federal law or regulation, and the Registrar has so determined in 26 27 writing. Notice of the proposed adoption of these regulations and the Registrar's determination shall be 28 published in the Virginia Register not less than 30 days prior to the effective date of the regulation. 29 5. Preliminary program permit fees of the Department of Environmental Quality assessed pursuant to subsection C of § 10.1-1322.2. 30 6. Regulations of the Pesticide Control Board adopted pursuant to subsection B of § 3.1-249.51 or 31 32 clause (v) or (vi) of subsection C of § 3.1-249.53 after having been considered at two or more Board 33 meetings and one public hearing. 34 7. Regulations of the regulatory boards served by (i) the Department of Labor and Industry pursuant 35 to Title 40.1 and (ii) the Department of Professional and Occupational Regulation or the Department of 36 Health Professions pursuant to Title 54.1 that are limited to reducing fees charged to regulants and 37 applicants. 38 8. The development and issuance of procedural policy relating to risk-based mine inspections by the 39 Department of Mines, Minerals and Energy authorized pursuant to §§ 45.1-161.82 and 45.1-161.292:55. 9. General permits issued by the (a) State Air Pollution Control Board pursuant to Chapter 13 40 41 (§ 10.1-1300 et seq.) of Title 10.1 or (b) State Water Control Board pursuant to the State Water Control 42 Law (§ 62.1-44.2 et seq.), Chapter 24 (§ 62.1-242 et seq.) of Title 62.1 and Chapter 25 (§ 62.1-254 et seq.) of Title 62.1, (c) Virginia Soil and Water Conservation Board pursuant to the Virginia Stormwater 43 Management Act (§ 10.1-603.1 et seq.) of Title 10.1, and (d) the development and issuance of general 44 wetlands permits by the Marine Resources Commission pursuant to subsection B of § 28.2-1307, if the 45 respective Board or Commission (i) provides a Notice of Intended Regulatory Action in conformance 46 with the provisions of subsection B of § 2.2-4007, (ii) following the passage of 30 days from the 47 **48** publication of the Notice of Intended Regulatory Action forms a technical advisory committee composed of relevant stakeholders, including potentially affected citizens groups, to assist in the development of 49 50 the general permit, (iii) provides notice and receives oral and written comment as provided in subsection 51 F of § 2.2-4007, and (iv) conducts at least one public hearing on the proposed general permit. 10. The development and issuance by the Board of Education of guidelines on constitutional rights 52 53 and restrictions relating to the recitation of the pledge of allegiance to the American flag in public 54 schools pursuant to  $\S$  22.1-202. 55 11. Regulations of the Board of the Virginia College Savings Plan adopted pursuant to § 23-38.77. 12. Regulations of the Marine Resources Commission. 56 57 13. Regulations adopted by the Board of Housing and Community Development pursuant to subsection D of § 36-99. 58 59 14. Amendments to the list of drugs susceptible to counterfeiting adopted by the Board of Pharmacy

HB355EH1

## HB355EH1

2 of 3

60 pursuant to subsection B of § 54.1-3307.

B. Whenever regulations are adopted under this section, the agency shall state as part thereof that it 61 62 will receive, consider and respond to petitions by any interested person at any time with respect to 63 reconsideration or revision. The effective date of regulations adopted under this subsection shall be in accordance with the provisions of § 2.2-4015, except in the case of emergency regulations, which shall 64 65 become effective as provided in subsection B of § 2.2-4012.

66 C. A regulation for which an exemption is claimed under this section or § 2.2-4002, or 2.2-4011 and that is placed before a board or commission for consideration shall be provided at least two days in 67 68 advance of the board or commission meeting to members of the public that request a copy of that 69 regulation. A copy of that regulation shall be made available to the public attending such meeting. 70

§ 54.1-3307. Specific powers and duties of Board.

71 A. The Board shall regulate the practice of pharmacy and the manufacturing, dispensing, selling, 72 distributing, processing, compounding, or disposal of drugs and devices. The Board shall also control the character and standard of all drugs, cosmetics and devices within the Commonwealth, investigate all 73 74 complaints as to the quality and strength of all drugs, cosmetics, and devices and take such action as 75 may be necessary to prevent the manufacturing, dispensing, selling, distributing, processing, 76 compounding and disposal of such drugs, cosmetics and devices that do not conform to the requirements 77 of law. 78

The Board's regulations shall include criteria for:

79 1. Maintenance of the quality, quantity, integrity, safety and efficacy of drugs or devices distributed, 80 dispensed or administered.

2. Compliance with the prescriber's instructions regarding the drug, its quantity, quality and directions 81 82 for use. 83

3. Controls and safeguards against diversion of drugs or devices.

4. Maintenance of the integrity of, and public confidence in, the profession and improving the 84 85 delivery of quality pharmaceutical services to the citizens of Virginia.

86 5. Maintenance of complete records of the nature, quantity or quality of drugs or substances 87 distributed or dispensed, and of all transactions involving controlled substances or drugs or devices so as 88 to provide adequate information to the patient, the practitioner or the Board.

89 6. Control of factors contributing to abuse of legitimately obtained drugs, devices, or controlled 90 substances.

91 7. Promotion of scientific or technical advances in the practice of pharmacy and the manufacture and 92 distribution of controlled drugs, devices or substances.

93 8. Impact on costs to the public and within the health care industry through the modification of 94 mandatory practices and procedures not essential to meeting the criteria set out in subdivisions 1 through 95 7 of this section.

96 9. Such other factors as may be relevant to, and consistent with, the public health and safety and the 97 cost of rendering pharmacy services.

98 B. The Board's regulations to implement the criteria set forth in subsection A shall include, but shall 99 not be limited to, the establishment and implementation of a pedigree system, as defined in subsection 100 D. The Board shall structure the implementation of the pedigree with limited application to certain schedules or certain drugs, upon finding that such drugs are more subject to counterfeiting. In order to 101 102 maintain a current and appropriate list of drugs susceptible to counterfeiting, the Board may amend such list in its regulations. Such amendments to the list shall be exempt from the requirements of Article 103 2 (§ 2.2-4006 et seq.) of the Administrative Process Act. The Board shall establish in regulation a 104 process for amending such list that provides notice and opportunity for public comment. The Board 105 shall limit the implementation of a pedigree system to those drugs that have left the normal distribution 106 channel as defined in subsection D. The pedigree shall also satisfy the requirements of 21 U.S.C. 107 108 § 353(e), regarding requirements for wholesale distributors of drugs in interstate commerce. The Board 109 may provide for exceptions to the pedigree requirements of this section for emergency medical reasons 110 as defined in regulation.

C. The Board may collect and examine specimens of drugs, devices and cosmetics that are 111 112 manufactured, distributed, stored or dispensed in the Commonwealth. 113

D. For the purposes of this section:

114 "Normal distribution channel" means a chain of custody for a prescription drug from initial sale by a pharmaceutical manufacturer, through acquisition and sale by one wholesale distributor as defined in 115 § 54.1-3401, that is not exempted pursuant to § 54.1-3401.1, until sale to a pharmacy or other person 116 dispensing or administering the controlled substance; or a chain of custody for a prescription drug from 117 initial sale by a pharmaceutical manufacturer, through acquisition and sale by one wholesale distributor 118 as defined in § 54.1-3401, that is not exempted pursuant to § 54.1-3401.1, to a chain pharmacy 119 120 warehouse to its intracompany pharmacies [; or a chain of custody for a prescription drug from initial sale by a pharmaceutical manufacturer to a chain pharmacy warehouse to its intracompany 121

122 pharmacies].

"Pedigree" means a paper document or electronic file recording each distribution of a controlled substance from sale by a pharmaceutical manufacturer through acquisition and sale by any wholesale distributor, as defined in § 54.1-3401 and not exempted pursuant to § 54.1-3401.1, until final sale to a 123 124 125 126 pharmacy or other person dispensing or administering the controlled substance. Returns from a pharmacy 127 to the originating wholesale distributor or pharmaceutical manufacturer shall not be subject to the

128 pedigree requirements of this section.